Treating Hypertension: Smarter, Sharper, and With New Tools<\/p>\n
Source: Medscape | June 2025<\/p>\n
Key Highlights:
\n1. BP Measurement First:
\nUse validated automated cuffs. Manual cuffs often misread by up to 10 mmHg. Technique matters: seated, supported, quiet, cuff on bare skin.
\n2. Treatment Targets by Guidelines:
\n\u2022 AHA\/ACC (U.S.): \u2264130\/80 mmHg
\n\u2022 AAFP (U.S.): \u2264140\/90 mmHg
\nAAFP = American Academy of Family Physicians; reflects a conservative primary care approach.
\n\u2022 KDIGO (Global): \u2264120\/80 mmHg
\nKDIGO is an international organization based in Belgium, widely followed by U.S. nephrologists for CKD care.
\n\u2022 ESC (Europe \u2013 not in original Medscape text): Start with <140\/90, then <130\/80 if tolerated especially in complicated HTN.
\n3. Therapeutic Strategy
\n\u2022 Prefer combining multiple low-dose agents over maxing out one
\n\u2022 Consider fixed triple-combination pills for ease and adherence
\n\u2022 Alcohol reduction: AHA allows up to 1\u20132 drinks\/day, while ESC advises complete abstinence
\n4. Workup of Resistant Hypertension:
\n\u2022 Many cases of \u201cresistant hypertension\u201d are due to nonadherence
\n\u2022 Check plasma renin and aldosterone in patients on 3+ agents
\n\u2022 Primary hyperaldosteronism is found in ~20% of these patients
\n\u2022 Do not stop meds (except MRAs) before measurement of ARR ; ensure potassium is repleted
\n\u2022 ARR >30 : High Aldosterone-to-Renin Ratio suggests diagnosis. It is a blood test used to screen for primary aldosteronism (also called Conn\u2019s syndrome), which is a common and treatable cause of resistant hypertension.; further confirmatory testing may be needed afterward.
\n5. When to Refer:
\n\u2022 CKD + MRA concern \u2192 nephrology
\n\u2022 Refer if patient is on 5+ antihypertensive agents
\n\u2022 Always screen for sleep apnea and perform renin-aldosterone testing beforehand<\/p>\n
\u2022 Outside Medscape:
\nAHA 2023 recommends adrenal CT if PA (primary aldosteronism) is confirmed, to rule out adrenal carcinoma (rare, <1%) and assess for surgery if feasible. CT adrenal is not a screening test; it should only be performed after biochemical confirmation. As stated in the Endocrine Society guidelines: \u201cCT imaging of the adrenal glands should be performed in all patients with confirmed primary aldosteronism.\u201d*
\nImportant clinical note: The ARR value should not be interpreted mathematically alone. The absolute levels matter: a high ARR with low aldosterone may be misleading. Generally, PAC (plasma aldosterone concentration) should be >15 ng\/dL and renin very low or suppressed. Always interpret ARR in clinical context<\/p>\n
Renal artery stenosis (RAS) is also a recognized secondary cause of resistant hypertension. It should be considered in patients with:
\n\u2022 Abrupt or severe-onset hypertension,
\n\u2022 Worsening renal function after starting ACEi\/ARB,
\n\u2022 Asymmetric kidney size or abdominal bruits, or
\n\u2022 Recurrent flash pulmonary edema or unexplained heart failure.*
\nIn such patients, imaging of the renal arteries is indicated.
\nPreferred modalities include CT angiography (CTA), MR angiography (MRA), or duplex renal Doppler ultrasound (depending on renal function and local expertise).
\nAccording to AHA\/ACC guidelines, CT angiography is often the first-line imaging in patients with preserved renal function.<\/p>\n